Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
08 Dezembro 2022 - 10:24PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation in the American Society of Hematology (ASH) Annual
Meeting and Exposition 2022 with a broad range of content covering
optical genome mapping’s (OGM) utility for research areas including
myeloid cancer, hematological malignancy, leukemia and blood
disorders.
ASH’s Annual Meeting brings together industry, medical, and
academic professionals to discuss advances in the field of blood
disease. The ASH conference will be held December 10-13,
2022, in New Orleans, Louisiana.
Poster presentations and scientific workshop sessions on OGM
include:
Poster Number |
Title |
Authors |
Presented |
2177 |
Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping
Analysis for Cytogenomic Characterization of Hematological
Malignancies: A Spanish Multicentric Study |
Puiggros A., Mallo M., Salido M., Gómez-García A., Cisneros A.,
García-Serra R., González-Gil C., Avetisyan G., Rodríguez-Rivera
M., Diaz-Gonzalez A., Granada I., Such E., Genescà E., Collado R.,
Ramírez-Orellana M., Solé F., Espinet B. |
December 10, 20225:30-7:30 PM CSTSession 803 |
3496 |
Combined Structural Variant and Mutation Profiling for
Comprehensive Characterization for Chromoanagenesis and TP53
Mutations in Myelodysplastic Syndromes with Complex Karyotype |
Kanagal-Shamanna, R., Yang H., Garcia-Manero G., Wei Y., Sasaki K.,
Chien K., Tang Z., Montalban-Bravo G., Kalia A., Luthra R.,
Medeiros J. |
December 11, 20226:00-8:00 PM CSTSession 803 |
3496 |
Combined Structural Variant and Mutation Profiling for
Comprehensive Characterization for Chromoanagenesis and TP53
Mutations in Myelodysplastic Syndromes with Complex Karyotype |
Kanagal-Shamanna, R., Yang H., Garcia-Manero G., Wei Y., Sasaki K.,
Chien K., Tang Z., Montalban-Bravo G., Kalia A., Luthra R.,
Medeiros J. |
December 11, 20226:00-8:00 PM CSTSession 803 |
4134 |
Optical Genome Mapping and Comprehensive Next Generation Sequencing
Panel for Myeloid Cancers: New Era of Complementary Profiling |
Sahajpal N., Mondal A., Jillella A., Kota V., Kolhe R. |
December 12, 20226:00-8:00 PM CSTSession 617 |
4148 |
Deciphering the Somatic and Germline Structural Variation Landscape
in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia by Whole
Genome Optical Mapping |
Brandes D., Brozou T., Nebral K., Bergmann A., Haas O., Köhrer S.,
Stanulla M., Fischer U., Borkhardt A., Wagener R. |
December 12, 20226:00-8:00 PM CSTSession 618 |
Session |
Title |
Author/Affiliation |
Presented |
Scientific Workshop |
Harnessing Emerging Technologies for Accurate Genomic
Classification, Prognostication and Therapeutic Discovery in
Myeloid Neoplasms |
Kanagal-Shamanna R., University of Texas M.D. Anderson Cancer
Center |
December 9, 20222:03-2:47 PM CST |
Dr. Blanca Espinet, who leads the translational research group
on hematological neoplasms at the Institut Hospital del Mar
d’Investigacions Mèdiques (IMIM) in Barcelona, Spain, participated
in a multi-site pilot study that will be presented at ASH as a
poster in session 803 on Saturday, December 10, 2022, from
5:30 to 7:30 pm. The study was conducted by the Spanish Working
Group on Optical Genome Mapping in Hematologic Malignancies, under
the Spanish Society of Hematology and Hemotherapy (SEHH). The
project aimed to describe the inter-laboratory reproducibility in
the identification and reporting of cytogenomic variants by OGM and
to outline the main causes of discrepancies among centers, to be
addressed in future OGM recommendations. Dr. Espinet commented, “We
are excited to attend ASH and to share information from our pilot
comparison study of OGM data analysis. We believe this study will
be of interest to ASH attendees as it underscores the need for
international guidelines and training mechanisms for OGM, which
should have benefits for innovative research.”
Erik Holmlin, president and chief executive officer of Bionano,
added, “We are delighted to see the broad range of presentations on
OGM at ASH this year. In particular, we are excited about the
poster covering the Spanish multi-site study, which we believe
shows the potential for the growing adoption and implementation of
OGM. Our customers continue to push forward conducting cutting-edge
research in the human genetics space and we are pleased to see them
share their research with the ASH community.”
More details on the conference can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome
analysis solutions that can enable researchers and clinicians to
reveal answers to challenging questions in biology and medicine.
The Company’s mission is to transform the way the world sees the
genome through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen,
Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information,
visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “should,” “potential,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
OGM’s utility for research in areas including myeloid cancer,
hematological malignancy, leukemia and blood disorders, and the
growth and adoption of OGM. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with:
global and macroeconomic events, such as the impact of the COVID-19
pandemic and the ongoing Ukraine-Russian conflict and related
sanctions, on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; failure of OGM to prove useful for research
in areas including myeloid cancer, hematological malignancy,
leukemia and blood disorders; failure of laboratories to adopt OGM;
the ability of our OGM solutions to offer the anticipated benefits
for and contributions to the areas reported in the presentations
given and posters made available at the ASH Annual Meeting 2022;
future study results contradicting the results reported in the
presentations given and posters made available at the ASH Annual
Meeting 2022; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024